Eli Lilly signs US$1B Alzheimer’s deal with AlzeCure Pharma for ACD680

USA—Eli Lilly has signed a licensing agreement worth up to US$1 billion with Swedish Alzheimer’s biotech AlzeCure Pharma, extending its aggressive 2026 deal-making strategy.

Under the agreement, Lilly will pay US$10 million upfront and up to more than US$990 million in development and commercial milestone payments, along with mid-single-digit royalties on future sales.

The partnership grants Lilly global rights to AlzeCure’s preclinical small-molecule candidate, ACD680, which targets the biology of Alzheimer’s disease.

ACD680 Mechanism and Therapeutic Rationale

ACD680 is designed as a gamma-secretase modulator to reduce the production of amyloid-beta peptides associated with plaque formation in the brain.

In particular, it lowers Aβ42 levels while promoting shorter, less toxic fragments such as Aβ37 and Aβ38, which AlzeCure believes may reduce neurotoxic aggregation.

The company is advancing the candidate as a potential disease-modifying therapy intended to slow or alter the progression of Alzheimer’s disease.

Alzheimer’s Landscape and Ongoing Scientific Debate

The deal strengthens Lilly’s presence in Alzheimer’s research, where it already markets Kisunla (donanemab), an anti-amyloid therapy approved in the United States in 2024.

However, amyloid-targeting drugs including Kisunla and Biogen’s Leqembi (lecanemab) continue to face scientific debate following a Cochrane review that described their effect on cognitive decline as “absent or trivial.”

Both companies have rejected the assessment, arguing that the review pooled failed candidates with approved therapies and therefore introduced methodological bias.

Despite ongoing controversy, amyloid beta remains a dominant target, with dozens of experimental therapies currently in development worldwide.

Lilly’s Expanding Deal-Making Strategy

The AlzeCure agreement adds to a rapid series of transactions by Lilly as it continues to expand its pipeline through external innovation and acquisitions.

Recently, the company signed a US$1.9 billion partnership with Ascidian to develop RNA-based exon-editing therapies for kidney diseases caused by single-gene mutations.

It also entered a US$1.26 billion licensing deal with Hanmi Pharmaceutical focused on the GLP-2 agonist sonepeglutide, alongside a separate US$3 billion collaboration with Haisco Pharmaceutical to advance novel drug candidates.

Earlier, Lilly completed US$3.83bn in vaccine-related acquisitions, including Curevo, LimmaTech Biologics, and The Vaccine Company, strengthening its infectious disease portfolio.

Pharmaceutical companies continue to increase dealmaking in neurology and metabolic disease as competition intensifies for next-generation biologics and small-molecule therapies.

Industry analysts note that Alzheimer’s research remains a high-risk but high-reward area, particularly as approved therapies face scrutiny while demand for disease-modifying options grows.